---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-23-000003"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:59:17.498944+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Entrada selects clinical candidate ENTR-601-45 for DMD exon 45 skipping; IND in H2 2024

## Summary
- ENTR-601-45 is an EEV-conjugated PMO targeting Duchenne patients amenable to exon 45 skipping.
- In vivo data showed >90% exon skipping in skeletal muscle of hDMD mouse model after single IV dose.
- More than 1,300 patients in US and Europe are exon 45 skipping amenable, per Entrada.
- Company plans to submit IND application in second half of 2024.
- Additional data expected at MDA Clinical & Scientific Conference in March 2023.

## SEC filing metadata
- accession: 0001689375-23-000003
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937523000003/0001689375-23-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937523000003/trda-20230109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-23-000003
- JSON: https://secwatch.observer/filing/0001689375-23-000003.json
- Plain text: https://secwatch.observer/filing/0001689375-23-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.